.Pharmacolibrary.Drugs.ATC.M.M05BA06 .Pharmacolibrary.Drugs.ATC.M.M05BA06| name: | IbandronicAcid |
| ATC code: | M05BA06 | route: | intravenous |
| n-compartments | 2 |
Ibandronic acid (ibandronate) is a bisphosphonate drug used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It reduces bone resorption by inhibiting osteoclast-mediated bone loss. Ibandronic acid is approved for clinical use in several countries as both oral and intravenous formulations.
Pharmacokinetic parameters in healthy postmenopausal women after a single intravenous dose.
Croom, KF, & Scott, LJ (2006). Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66(12) 1593–1603. DOI:10.2165/00003495-200666120-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16956306
Pillai, G, et al., & Steimer, JL (2006). Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. International journal of clinical pharmacology and therapeutics 44(12) 655–667. DOI:10.5414/cpp44655 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17190376
Nakai, K, et al., & Kawanishi, T (2016). The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. European journal of drug metabolism and pharmacokinetics 41(2) 139–147. DOI:10.1007/s13318-014-0242-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25476995